The assessment of PD-L1 expression in tumor tissue or circulating biomarkers such as urine samples may help identify patients who are likely to benefit from immunotherapy, thus guiding treatment decisions and improving clinical outcomes [12]. This evidence concerns the gene CD274 and neoplasm.